Press Releases

TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that Damian Marron, CEO, TxCell, will present at Biotech Showcase™ 2014, taking place January...

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog(R),...

Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased to announce the signing of a licensing and partnership agreement on GPCR biosensor technology...

Creating an Innovate Plan for the USA Biosimilars Market: presentations from Sandoz, IMS Health, Bristows, PRA International, Celltrion, MedImmune, Novartis, Lonza Biologics and others. After the phenomenal success of our Biosimilars and Biobetters event hosted in...

Eureka Science proudly announces the collaboration with international societies and organizations for the events; the “6th International Conference on Drug Discovery and Therapy” and the “3rd Biotechnology World Congress” to be held in Dubai, UAE, from February 10th -...

FibroGen Inc. (FibroGen) today announced the presentation of a Phase 2 subgroup analysis comparing treatment response to roxadustat (FG-4592) a first-in-class oral compound in late stage development in incident peritoneal dialysis (PD) patients and incident hemodialysis (HD) patients for...

The partnership is based on Oncodesign's Nanocyclix(R) technology platform for next generation kinase inhibitors and UCB’s expertise in neurology. Oncodesign, a drug discovery company and oncology pharmacology service provider, announces today that it has entered...